Moderna will spike another 25% from current levels after encouraging progress on coronavirus vaccine, Goldman says

· *Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results.*
· *Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against COVID-19 infection. Shares jumped as much as 39% on the...